Company: MYGN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000899923-25-000086
Chunk: 116

Company: MYRIAD GENETICS INC
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 2
Chunk 116
---
 to the same period in the prior year due to a 17% increase in average revenue per test partially offset by an 8% decrease in volume. These increases in Hereditary Cancer and Prenatal revenues were partially offset by decreases in Pharmacogenomics and Tumor Profiling revenue. Pharmacogenomics revenues decreased $5.2 million for the three months ended June 30, 2025 compared to the same period in the prior year due to a 16% decrease in average revenue per test. We expect that Pharmacogenomics revenues during the remainder of fiscal year 2025 and thereafter will continue to be negatively impacted by UnitedHealthcare's change in GeneSight test coverage under its commercial and individual exchange benefits plans. Tumor Profiling revenue decreased $1.2 million primarily due to the sale of our EndoPredict business in August 2024. 

23

Cost of Revenue

Three months ended June 30,(in millions)20252024Change% ChangeCost of revenue$61.3 $64.4 $(3.1)(5)%Cost of revenue as a % of total revenue28.8 %30.4 %

Cost of revenue for the three months ended June 30, 2025 decreased $3.1 million compared to the same period in the prior year primarily due to a reduction in the cost per test for the current period driven by reductions in the cost of laboratory reagents and supplies. 

Research and Development Expense

Three months ended June 30,(in millions)20252024Change% ChangeResearch and development expense$25.6 $27.1 $(1.5)(6)%Research and development expense as a % of total revenue12.0 %12.8 % 

Research and development expenses for the three months ended June 30, 2025 were relatively consistent with the expenses incurred in the same period of the prior year, reflecting stable operating activities across the business. We remain committed to disciplined cost management while maintaining investments in key strategic areas, such as research and development. 

Sales and Marketing Expense

Three months ended June 30,(in millions)20252024Change% ChangeSales and marketing expense$71.9 $72.8 $(0.9)(1)%Sales and marketing expense as a % of total revenue33.7 %34.4 %

Sales and marketing expenses for the three months ended June 30, 2025 were relatively consistent with the expenses incurred in the same period of